Weill Cornell Medical College-New York Presbyterian Hospital

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder	Recruiting	Phase 3	2026-10-07	NCT05568719
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)	Disease Attributes, Hemic and Lymphatic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, bone marrow disorder, hematologic disorder, myelodysplastic syndrome	Active, not recruiting	Phase 2 / Phase 3	2026-07-17	NCT02598661
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.	B-cell neoplasm, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, graft versus host disease, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 4	2025-10-30	NCT03229200

Clinical trials